Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats

Vascular Pharmacology

Volumn 48, Issue 4-6, 2008, Pages 165-173

  Vernerová, Zdenka ^a,b   Kramer, Herbert J ^c   Bäcker, Angela ^c   Červenka, Luděk ^a,b,d   Opočenský, Martin ^a,d   Husková, Zuzana ^a,d   Vaňourková, Zdeňka ^a,d   Eis, Václav ^a,b   Chabova, Vera Certikova ^a,b,d   Tesař, Vladimír ^b   Malý, Jan ^a   Vaněčková, Ivana ^a,d  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d Ctr for Exp Cardiovasc Research   (Czech Republic)

Author keywords

End organ damage; ETA and ETB receptors; Heterozygous transgenic Ren 2 rats; Hypertension; Podocytes

Indexed keywords

ATRASENTAN; BOSENTAN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DESMIN; ENDOTHELIN 1; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIET; GLOMERULOSCLEROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SURVIVAL; TRANSGENIC RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; BODY WEIGHT; ENDOTHELIN-1; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HETEROZYGOTE; HYPERTENSION, MALIGNANT; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICROSCOPY, ELECTRON; ORGAN SIZE; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; RENIN; SODIUM, DIETARY; SURVIVAL RATE;

EID: 43849113758     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.01.009     Document Type: Article

References (32)

1. Barton M., Mullins J.J., Bailey M.A., and Kretzler M. Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials. Hypertension 48 (2006) 834-837
2. Bouallegue A., Daou G.B., and Srivastava A.K. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr. Vasc. Pharmacol. 5 (2007) 45-52
3. Brunner F., Bras-Silva C., Cerdeira A.S., and Leite-Moreira A.F. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol. Ther. 111 (2006) 508-531
4. Callahan M.F., Li P., Ferrario C.M., Ganten D., and Morris M. Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 27 (1996) 573-577
5. Davenport A.P., and Maguire J.J. Endothelin. Handb. Exp. Pharmacol. (2006) 295-329
6. Debiec H., Guigonis V., Mougenot B., Haymann J.P., Bensman A., Deschenes G., and Ronco P.M. Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases. J. Am. Soc. Nephrol. 14 Suppl 1 (2003) S27-S32
7. Fink G., Li M., Lau Y., Osborn J., and Watts S. Chronic activation of endothelin B receptors: new model of experimental hypertension. Hypertension 50 (2007) 512-518
8. Floege J., Kriz W., Schulze M., Susani M., Kerjaschki D., Mooney A., Couser W.G., and Koch K.M. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J. Clin. Invest. 96 (1995) 2809-2819
9. Ge Y., Bagnall A., Stricklett P.K., Strait K., Webb D.J., Kotelevtsev Y., and Kohan D.E. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. Renal. Physiol. 291 (2006) F1274-F1280
10. Heller J., and Hellerova S. Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the Prague hypertensive rat. Kidney Blood Press. Res. 21 (1998) 445-451
11. Hirata Y., Takagi Y., Fukuda Y., and Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78 (1989) 225-228
12. Huskova Z., Kramer H.J., Vanourkova Z., and Cervenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J. Hypertens. 24 (2006) 517-527
13. Kohan D.E. The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr. Opin. Nephrol. Hypertens. 15 (2006) 34-40
14. Kunes J., and Zicha J. Developmental windows and environment as important factors in the expression of genetic information: a cardiovascular physiologist's view. Clin. Sci. (Lond.) 111 (2006) 295-305
15. Matsumura Y., Hashimoto N., Taira S., Kuro T., Kitano R., Ohkita M., Opgenorth T.J., and Takaoka M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 33 (1999) 759-765
16. Morigi M., Buelli S., Zanchi C., Longaretti L., Macconi D., Benigni A., Moioli D., Remuzzi G., and Zoja C. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am. J. Pathol. 169 (2006) 1965-1975
17. Nouwen E.J., Verstrepen W.A., Buyssens N., Zhu M.Q., and De Broe M.E. Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat. Lab. Invest. 70 (1994) 479-493
18. Opocensky M., Kramer H.J., Backer A., Vernerova Z., Eis V., Cervenka L., Certikova V C., Tesar V., and Vaneckova I. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48 (2006) 965-971
19. Pavenstadt H., Kriz W., and Kretzler M. Cell biology of the glomerular podocyte. Physiol. Rev. 83 (2003) 253-307
20. Pollock D.M., and Pollock J.S. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol. Renal. Physiol. 281 (2001) F144-F150
21. Pollock D.M., Portik-Dobos V., Procter C., Gariepy C.E., and Yanagisawa M. Arterial pressure response to endothelin-1 and sarafotoxin 6c in rescued endothelin-B-deficient rats. J. Cardiovasc. Pharmacol. 36 (2000) S82-S85
22. Remuzzi G., Benigni A., and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116 (2006) 288-296
23. Roux S., Breu V., Ertel S.I., and Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. 77 (1999) 364-376
24. Sanai T., Sobka T., Johnson T., el-Essawy M., Muchaneta-Kubara E.C., Ben G.O., el O.S., and Nahas A.M. Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy. Diabetologia 43 (2000) 91-100
25. Saito T., Sumithran E., Glasgow E.F., and Atkins R.C. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int. 32 (1987) 691-699
26. Schiffrin E.L. Vascular endothelin in hypertension. Vascul. Pharmacol. 43 (2005) 19-29
27. Strutz F., and Muller G.A. Transdifferentiation comes of age. Nephrol. Dial. Transplant 15 (2000) 1729-1731
28. Vaneckova I., Kramer H.J., Backer A., Vernerova Z., Opocensky M., and Cervenka L. Early Endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46 (2005) 969-974 [part 2]
29. Vaneckova I., Kramer H.J., Backer A., Schejbalova S., Vernerova Z., Eis V., Opocensky M., Dvorak P., and Cervenka L. Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vascul. Pharmacol. 45 (2006) 163-170
30. Vassileva I., Mountain C., and Pollock D.M. Functional role of ETB receptors in the renal medulla. Hypertension 41 (2003) 1359-1363
31. Whitworth C.E., Veniant M.M., Firth J.D., Cumming A.D., and Mullins J.J. Endothelin in the kidney in malignant phase hypertension. Hypertension 26 (1995) 925-931
32. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415